Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2015

View Archived Issues

GANT-61 induces remyelination in mouse models of multiple sclerosis

Bionomics and Merck & Co. extend collaboration for pain medications

177Lu-DOTATATE improves progression-free survival in midgut NET patients

Study reveals selenoprotein P as a potential marker of insulin sensitivity

University of Pennsylvania reports AAVs expressing human OTC

Molecular Templates collaborates with MD Anderson Cancer Center on MT-3724

IGF-I and insulin may promote pancreatic cancer

UCB reports results from trial comparing Vimpat to Tegretol Retard in epilepsy

BlinkBio forms discovery collaboration with Janssen Pharmaceuticals

Caribou Biosciences and DuPont partner to develop CRISPR-Cas technology

Roche to acquire Adheron Therapeutics

Control of CAR T-cell therapy using heterodimerization stimulated by a small molecule

Sebacia completes enrollment in trial of acne treatment

CF-102 receives EMA orphan drug designation for HCC

Universiteit Antwerpen patents KLK4 inhibitors

Development of Lilly's evacetrapib terminated due to insufficient efficacy

Takeda Pharmaceutical develops PKC theta inhibitors

Changzhou Jiekai Pharmatech discloses AXL inhibitors

Efficacy and safety of MT-1303 in RRMS

Concert Pharmaceuticals earns milestone from Celgene for CTP-730

Ocrelizumab: results from ORATORIO study

Astellas Pharma and Immunomic Therapeutics partner for LAMP-vax products

FDA awards breakthrough therapy designation to RBX-2660 for recurrent C. difficile infection

FDA approves Opdivo for non-squamous NSCLC

Dynavax begins trial evaluating SD-101 in combination with Keytruda

EBOVAC-Salone trial begins in Sierra Leone

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...